Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024

Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies,announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene's shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions was published in theBulletin des Annonces Légales Obligatoires(BALO) n° 42 of April 5, 2024.These notices...

Illkirch Graffenstaden, 24/04/2024 (informazione.it - comunicati stampa - economia)

announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene's shareholders is available.

The notice of meeting, comprising the agenda and the draft resolutions was published in the (BALO) n° 42 of April 5, 2024.

These notices include information on how to attend and vote at the General Meeting.

The General Meeting will be broadcast live on the Company's website ( www.transgene.fr under “Investors - Shareholders' Meeting”) and the video will also be available later within the time period provided for by the regulations.

The procedures and rules relative to the holding of this shareholder meeting, as well as the exercise of the right to request documents and submit written questions, are set out in the notice of meeting published on April 5, 2024 and are also posted at www.transgene.fr/AG2024 . 

Contacts

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the ® platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone.

With Transgene's ® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The ® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at: www.transgene.fr
Follow us on social media: X (formerly Twitter): @TransgeneSA – LinkedIn: @Transgene

Attachment